20th Sep 2013 07:28
LONDON (Alliance News) - GlaxoSmithKline PLC's treatments for asthma and chronic obstructive pulmonary disease Friday got approval for marketing in Japan and moved closer to getting full European approval after the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion Thursday.
The CHMP has recommended marketing authorisation for the products under the proposed brand name RELVAR ELLIPTA.
In a separate statement Friday Glaxo announced that its RELVAR ELLIPTA treatment had been given approval in Japan by the Japanese Ministry of Health, Labour and Welfare.
Shares in the pharmaceutical company was trading down 0.54% at 1,567.50 pence Friday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline